HEALTH● LOW1h ago · Sep 30, 2026, 10:04 AM
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1
Seeking Alpha Tech · global
AbbVie's experimental drug ABBV-295 showed up to 9.8% weight loss in Phase 1 trials. This indicates a promising early development for a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH29m agoWomen face a "diagnostic odyssey" at the doctor. This plan aims to help.CBS NewsHEALTH29m agoWe're Going Backwards: The $20 Billion Plan to Close the Gender Healthcare GapCBS NewsHEALTH29m agoTravel plans? Here's what to know as measles exposures reach trains and gamesNPR NewsHEALTH32m agoWoman who had wrong leg amputated during surgery for cancer treatment sues hospitalThe Independent World